Halozyme Therapeutics, Inc. (HALO) Misses Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.66 --0%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.31 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
- DA Davidson Reiterates Buy Rating on Boost Run (BRUN)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
